Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02419573
Other study ID # HL077863-PART
Secondary ID 5U01HL077863UH2H
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2015
Est. completion date December 1, 2017

Study information

Verified date December 2018
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the trial is to determine if 72-hour survival after out-of-hospital cardiac arrest (OHCA) is improved with initial endotracheal intubation (ETI) over initial laryngeal tube (LT) airway management strategies.


Description:

The primary objective of the trial is to determine if 72-hour survival after out-of-hospital cardiac arrest (OHCA) is improved with initial endotracheal intubation (ETI) over initial laryngeal tube (LT) airway management strategies.

The null hypothesis is that 72-hour survival is similar between primary Laryngeal Tube (LT) SGA and primary ETI airway management strategies.

Evaluated secondary outcomes will include return of spontaneous circulation, survival to hospital discharge, neurologically intact survival at hospital discharge, airway management performance, and clinical adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 3004
Est. completion date December 1, 2017
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Out-of-hospital cardiac arrest (OHCA)

- Adult (age =18 years or per local interpretation)

- Non-traumatic etiology

- Initiation of ventilatory support (e.g., bag-valve-mask device, non-rebreather mas, etc.)

Exclusion Criteria:

- Known pregnant women

- Known prisoners

- Major facial trauma (visible major deformity, copious oral bleeding, etc)

- Major bleeding or exsanguination (e.g., major upper or lower GI bleed, visceral perforation, major uncontrolled bleeding from laceration or injury)

- Patient receiving initial care by a non-PART participating EMS agency capable of performing ETI, LT, or other advanced airway management

- Patients with ET tube, LT or other advanced airway device inserted prior to participating EMS agency arrival (e.g., inserted by healthcare facility personnel)

- Patients with a pre-existing tracheostomy

- Obvious asphyxial cardiac arrest (e.g., choking, foreign body aspiration, angioedema, epiglottitis, trauma to mouth and face, etc.)

- Patients with a left ventricular assist device (LVAD) or total artificial heart (TAH)

- Patients with pre-existing written "do-not-attempt-resuscitation" (DNAR) orders

- Inter-facility transports

- Patients with a "do not enroll" bracelet

Study Design


Intervention

Device:
Endotracheal Intubation
In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
Laryngeal Tube (King)
In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.

Locations

Country Name City State
United States Alabama Resuscitation Center Birmingham Alabama
United States Dallas Center for Resuscitation Research, University of Texas Southwestern Medical Cente Dallas Texas
United States Milwaukee Resuscitation Network, Medical College of Wisconsin Milwaukee Wisconsin
United States The Pittsburgh Resuscitation Network, University of Pittsburgh Pittsburgh Pennsylvania
United States Portland Resuscitation Outcomes Consortium, Oregon Health & Sciences University Portland Oregon
United States University of Washington (Data Coordinating Center) Seattle Washington

Sponsors (4)

Lead Sponsor Collaborator
University of Alabama at Birmingham American Heart Association, National Heart, Lung, and Blood Institute (NHLBI), The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients Alive at 72 Hours After Episode. Number of patient alive at 72 hours after episode. 72 hours
Secondary Return of Spontaneous Circulation (ROSC) Presence of palpable pulses on Emergency Department arrival. Patients pronounced dead in the field coded as ROSC=[none]. Patients will be followed from the time of the CA until death or ROSC whichever occurs first. The time frame for this secondary outcome may vary from minutes to hours, but is not expected to last longer than 12 hours.
Secondary Number of Patients Alive at Hospital Discharge Number of patients alive at time hospital discharge. From enrollment through end of hospital course. Maximum time interval not specified. Maximum time interval observed in study was 138 days.
Secondary Number of Patients With Favorable Neurologic Status on Hospital Discharge Number of patients with favorable neurologic status, defined as Modified Rankin Scale (MRS) <=3.
MRS values for neurologic outcome include:
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
From enrollment through end of hospital course.
See also
  Status Clinical Trial Phase
Recruiting NCT06048068 - Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events N/A
Recruiting NCT05558228 - Accuracy of Doppler Ultrasound Versus Manual Palpation of Pulse in Cardiac Arrest
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Completed NCT04619498 - Effectiveness of an Interactive Cognitive Support Tablet App to Improve the Management of Pediatric Cardiac Arrest N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT02352350 - Lactate in Cardiac Arrest N/A
Completed NCT03024021 - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed NCT02247947 - Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome
Completed NCT02275234 - Care After Resuscitation
Completed NCT01936597 - Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage N/A
Completed NCT01944605 - Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest N/A
Completed NCT01972087 - Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest N/A
Active, not recruiting NCT01239420 - Norwegian Cardio-Respiratory Arrest Study
Completed NCT00880087 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial N/A
Completed NCT01191736 - Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice N/A
Completed NCT00878644 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial Phase 3
Completed NCT00729794 - Vasopressin, Epinephrine, and Steroids for Cardiac Arrest Phase 3
Recruiting NCT00441753 - Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest N/A
Completed NCT00347477 - Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest Phase 3